Navigation Links
Drug in New Hepatitis C Clinical Trial
Date:8/24/2007

BRISBANE, Australia, Aug. 24 /PRNewswire/ -- Physicians at Southern Health have started a phase IIa clinical trial designed to test the efficacy of a new strategy for defeating hepatitis C viral infection, one of the toughest infectious diseases in the modern world.

Implicit Bioscience's drug, oglufanide disodium, which works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.

"The drugs currently in use fail to control this disease in about one half of all patients," said Dr Ian Frazer, Implicit's Chief Scientific Officer. "So there is a compelling need for new and better therapies, and we hope that oglufanide disodium may control or reverse the suppression of the immune system which the hepatitis virus uses to defeat our normally healthy defenses."

Dr Frazer is well known as the co-inventor of the recently approved vaccine for papillomavirus, which is designed to prevent cervical cancer.

Dr William Sievert, who is the Principal Investigator for the trial, welcomed the opportunity to study the action of oglufanide disodium in his busy liver diseases clinic at the Monash Medical Centre, which is part of the Southern Health network. "It is an important opportunity for patients to be involved in a new trial such as this, in which new treatment prospects are explored."

Oglufanide disodium was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by the privately-owned Brisbane biotech company Implicit Bioscience Pty Ltd in 2005.

The phase IIa trial of intranasal oglufanide disodium will complement the ongoing phase Ib study of subcutaneously administered drug at the Princess Alexandra Hospital in Brisbane.

Oglufanide disodium regulates the body's innate immune response to defeat in
'/>"/>

SOURCE Implicit Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 , Registry provides ... of life and treatment satisfaction [ 1 ...        (Photo: ... September 2014, Barcelona, Spain : Daiichi ... oF thromboembolic events-European Registry in Atrial Fibrillation (PREFER in ...
(Date:9/2/2014)... 2014  Edison Nation Medical, the premier healthcare ... American Association for Respiratory Care ( AARC ), ... Edison Nation Medical, which brings 12+ years experience ... their innovation ideas, will work with AARC to ... 50,000 respiratory therapists in bringing their product innovation ...
(Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... focus, and new drug-eluting technologies to drive lower extremity ... Millennium Research Group WALTHAM, Mass., May 28 ... for Peripheral Vascular (PV) Devices 2009 report, rapid ... lower extremity peripheral artery disease in Europe is being ...
... MATEO¿ Calif.¿ May 28 Results and additional analyses ... clinical trial of Corthera,s investigational drug relaxin for the ... the Heart Failure Congress, the annual meeting of the ... in Nice, France. Marco Metra, M.D., professor of ...
Cached Medicine Technology:Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 2Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 3Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2
(Date:9/2/2014)... be a new salve to dominate medicine cabinets of the ... Salamanders may not be the cuddliest of animals, but they ... damaged body parts. Now, a new report published in the ... , identifies a small protein (called a "peptide") from the ... the secret of this amazing wound healing trick in humans. ...
(Date:9/2/2014)... made it clear that a mother,s eating habits prior ... profound impact on her offspring and their propensity for ... the mechanisms behind this phenomenon were unclear. According to ... The FASEB Journal F , scientists using ... mother,s diet and an offspring,s risk of future obesity. ...
(Date:9/2/2014)... 2014 Concorde Career College North ... receive the 2014 Excellence in Community Service Award ... Colleges (ACCSC). , Every year, the Accrediting Commission ... who make outstanding contributions in their local community ... the scope and impact of the community service ...
(Date:9/2/2014)... that the key to more youthful immune function might ... published in the Journal of Leukocyte Biology ... of old mice had different responses to Mycobacterium ... changes were reversed by ibuprofen. , "Inflammation in old ... Joanne Turner, Ph.D., a researcher involved in the work ...
(Date:9/2/2014)... Splashtop Inc. , the worldwide ... NTT DoCoMo to deliver Splashtop Business Lite ... Lite is included in NTT DoCoMo’s “Business Plus” program. ... that empower users to remote access their corporate computers ... 18 million users worldwide. Splashtop delivers the best ...
Breaking Medicine News(10 mins):Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... Barbara Davis Center for Childhood Diabetes at the University ... against type 1 diabetes: The Juvenile Diabetes Research Foundation ... JDRF Autoimmunity Center at the Barbara Davis Center for ... Autoimmunity Center will receive approximately $1 million a year ...
... are lucky in love. , At least thats how ... research on the mating habits and nervous systems of ... both the voles behavior and their brains, appears in ... Academy of Sciences. , Prairie voles, aka Microtus ochrogaster, ...
... 28 The Department of,Veterans Affairs (VA) today ... Marion, Ill., hospital. The VA today released the ... at the Marion,facility., VA,s Inspector General was ... for Health, on September 10, 2007 and also ...
... Reasons for the association are unknown, researchers say , , ... Korean study found frequent snoring was associated with the ... they aren,t sure why. , "The mechanisms underlying the ... said the report, published in the Jan. 28 issue ...
... to Launch Vitals.com Which Offers Free Comprehensive Doctor ... Information and ... ), one of the,nation,s top 10 public relations firms, today announced ... and execute a,comprehensive communications program for the free, online doctor evaluation,service., ...
... the use of financial,incentives for health care ... non-profit National Business,Coalition on Health (NBCH) recently ... discuss an emerging trend in employer-sponsored health,care: ... choice of,healthier lifestyles and high value medical ...
Cached Medicine News:Health News:JDRF to establish an autoimmunity center at University of Colorado Denver 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 2Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 4Health News:Study Links Snoring to Chronic Bronchitis 2Health News:MWW Group Selected by First-Ever Online Doctor Evaluation Service Vitals.com 2Health News:National Business Coalition on Health Convenes Multi-Stakeholder Leadership Group to Address Value Based Purchasing Trends 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint ... align the hand with ulnar deviation at ... impede grasp or pinch. Radial and ulnar ... ensure unimpeded flexion and extension. Padded, malleable ...
... immobilizes and positions the elbow at 122 ... prominent. Restricts full extension and flexion to ... helps prevent pain and irritation due to ... post-cast removal. Rigid, high-density beige polyethylene shell ...
... Orthosis For quick, efficient immobilization of ... immobilizes and protects the fracture and ... comfort, support, and conformity to the ... shell may be gently heated (with ...
Medicine Products: